Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Carter-Harrison Research Bldg (MR6), 345 Crispell Drive, Charlottesville, VA, 22908, USA.
Parasitol Res. 2022 Aug;121(8):2453-2455. doi: 10.1007/s00436-022-07567-8. Epub 2022 Jun 9.
Trichomoniasis is a sexually transmitted infection in humans caused by the protozoan Trichomonas vaginalis, the leading causative agent of vaginitis in women and urethritis in men worldwide. Metronidazole is the standard treatment for trichomoniasis, with tinidazole as the second line. There are currently no FDA-approved non-nitroimidazole alternative treatments for resistant strains. This study compares the efficacy of a newly synthesized non-nitroimidazole oral drug, amixicile, to that of both metronidazole and the synthetic precursor of amixicile, nitazoxanide with in vitro sensitivity testing. One standard strain from ATCC and three patient-isolated strains of T. vaginalis were used to compare treatments under anaerobic conditions. The minimum inhibitory concentration for metronidazole, nitazoxanide, and amixicile were 12.5 μM, 100 μM, and 6.25 μM, respectively. These results suggest that amixicile may be highly active against T. vaginalis and warrants further investigation as a potential alternative to metronidazole in the treatment of trichomoniasis.
滴虫病是一种由原生动物阴道毛滴虫引起的性传播感染，是全球女性阴道炎和男性尿道炎的主要致病因素。甲硝唑是治疗滴虫病的标准药物，替硝唑是二线药物。目前，对于耐药菌株，还没有获得 FDA 批准的非硝基咪唑类替代治疗方法。本研究比较了新合成的非硝基咪唑类口服药物阿莫昔立与甲硝唑和阿莫昔立合成前体硝唑尼特在体外药敏试验中的疗效。使用从 ATCC 获得的一个标准菌株和三个患者分离的阴道毛滴虫菌株，在厌氧条件下比较治疗效果。甲硝唑、硝唑尼特和阿莫昔立的最低抑菌浓度分别为 12.5 μM、100 μM 和 6.25 μM。这些结果表明，阿莫昔立可能对阴道毛滴虫具有高度活性，值得进一步研究，作为治疗滴虫病的甲硝唑替代药物。
